53.58
1.83%
-1.1376
Crinetics Pharmaceuticals Inc stock is traded at $53.58, with a volume of 454.96K.
It is down -1.83% in the last 24 hours and down -9.09% over the past month.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
See More
Previous Close:
$54.72
Open:
$54.35
24h Volume:
454.96K
Relative Volume:
0.68
Market Cap:
$5.05B
Revenue:
$4.72M
Net Income/Loss:
$-258.54M
P/E Ratio:
-15.71
EPS:
-3.41
Net Cash Flow:
$-185.05M
1W Performance:
-10.48%
1M Performance:
-9.09%
6M Performance:
+4.51%
1Y Performance:
+79.13%
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA
Compare CRNX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
CRNX | 53.74 | 5.05B | 4.72M | -258.54M | -185.05M | -3.41 |
VRTX | 467.45 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 760.74 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 564.72 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 230.44 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.56 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-06-24 | Initiated | Citigroup | Buy |
Jan-16-24 | Initiated | Morgan Stanley | Overweight |
Dec-21-23 | Initiated | Jefferies | Hold |
Nov-20-23 | Resumed | JP Morgan | Overweight |
Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
Aug-31-23 | Initiated | Oppenheimer | Outperform |
Apr-24-23 | Initiated | Piper Sandler | Overweight |
Mar-30-23 | Initiated | Robert W. Baird | Outperform |
Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
Nov-23-21 | Initiated | Evercore ISI | Outperform |
Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-23-19 | Initiated | ROTH Capital | Buy |
Feb-14-19 | Initiated | H.C. Wainwright | Buy |
Aug-13-18 | Initiated | JP Morgan | Neutral |
Aug-13-18 | Initiated | Leerink Partners | Outperform |
Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Leerink Partnrs Has Strong Forecast for CRNX FY2024 Earnings - MarketBeat
Learn to Evaluate (CRNX) using the Charts - Stock Traders Daily
FY2024 Earnings Forecast for CRNX Issued By Lifesci Capital - Defense World
HC Wainwright Has Bearish Estimate for CRNX FY2024 Earnings - Defense World
Steven Cohen's Recent Transaction in Crinetics Pharmaceuticals Inc - GuruFocus.com
Crinetics Pharmaceuticals : 2024 Evercore 7th Annual HealthCONx Conference - Marketscreener.com
Crinetics Pharmaceuticals : 2024 Cantor Global Healthcare Conference - Marketscreener.com
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences - The Manila Times
Crinetics Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | CRNX Stock News - StockTitan
EcoR1 Capital, LLC Increases Stake in Crinetics Pharmaceuticals Inc - GuruFocus.com
HC Wainwright Has Pessimistic View of CRNX FY2024 Earnings - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 52-Week High Following Analyst Upgrade - Defense World
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline - GlobeNewswire
Crinetics Unveils Breakthrough Cancer Drug Platform, Reports Positive Phase 2 Trial Results | CRNX Stock News - StockTitan
Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023) - Yahoo Finance
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Crinetics Pharmaceuticals (NASDAQ:CRNX) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q3 2024 Earnings Call Transcript - Insider Monkey
Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highl - GuruFocus.com
Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Acromegaly Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Amryt Pharma, Chiasma, Recordati, Novartis, Crinetics Pharma, Camurus AB, Ionis Pharma - The Globe and Mail
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Crinetics Pharmaceuticals to Showcase Pipeline Advancements - GlobeNewswire
Crinetics Pharmaceuticals, Inc. Announces Additional Data from the 2 Study of Its Investigational Drug Atumelnant in Cah Is Anticipated by Early 2025 - Marketscreener.com
Crinetics' Breakthrough: Phase 2 Trial Success & Novel NET Treatment Pipeline Advances | CRNX Stock News - StockTitan
Acromegaly Market Forecasted to Surge in Coming Years, - openPR
CRNXCrinetics Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Grants 99,500 Stock Options to New Hires at $60.69, Expanding Team | CRNX Stock News - StockTitan
Lisanti Capital Growth LLC Increases Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals (CRNX) to Release Earnings on Tuesday - Defense World
Fiera Capital Corp Sells 14,334 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Wellington Management Group LLP Reduces Stake in Crinetics Pharm - GuruFocus.com
CRNX (Crinetics Pharmaceuticals) Total Inventories : $0.00 Mil (As of Jun. 2024) - GuruFocus.com
(CRNX) Technical Pivots with Risk Controls - Stock Traders Daily
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by abrdn plc - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Crinetics Pharmace - GuruFocus.com
Acromegaly Pipeline 2024: Clinical Trials Assessment, FDA - openPR
Investors might be losing patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) increasing losses, as stock sheds 5.6% over the past week - Yahoo Finance
Moody Aldrich Partners LLC Sells 11,053 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 1-Year HighHere's What Happened - MarketBeat
Analysts Set Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Target Price at $68.55 - MarketBeat
State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals - Yahoo Finance
Crinetics Pharmaceuticals’ $500 Million Common Stock Offering - Global Legal Chronicle
Crinetics Pharmaceuticals outlines executive transition By Investing.com - Investing.com Australia
Crinetics Pharmaceuticals outlines executive transition - Investing.com India
Crinetics Pharmaceuticals Inc’s results are impressive - US Post News
Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 12-Month HighWhat's Next? - MarketBeat
Crinetics Pharmaceuticals Inc (CRNX) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Crinetics Pharmaceuticals Inc Stock (CRNX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Pizzuti Dana | Chief Med and Dev Officer |
Oct 03 '24 |
Sale |
54.63 |
14,375 |
785,306 |
28,507 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):